![Adrienne Weil](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Adrienne Weil
Geen lopende functies
Profiel
Adrienne Weil has been General Counsel of BiPar Sciences, Inc. since 2008.
Prior to joining BiPar Sciences, she worked at Orrick, Herrington & Sutcliffe LLP.
She has experience in representing issuers, corporate borrowers, underwriters, credit providers and investors in all aspects of financing and multiparty agreements.
Ms. Weil received a bachelor's degree from the University of California, Los Angeles and a Law degree from the Loyola Law School.
Eerdere bekende functies van Adrienne Weil
Bedrijven | Functie | Einde |
---|---|---|
Orrick, Herrington & Sutcliffe LLP
![]() Orrick, Herrington & Sutcliffe LLP Miscellaneous Commercial ServicesCommercial Services Orrick, Herrington & Sutcliffe LLP engages in the provision of legal services. Its practices include: antitrust and competition; banking and finance; capital markets; copyright, trademark and false advertising; cyber, privacy and data innovation; employment law and litigation; energy; financial services litigation; global compliance and regulatory, infrastructure; intellectual property; patents; public finance; real estate; securities litigation; supreme court and appellate; tax advocacy; technology transactions; trials; and white collar, investigations, securities litigation and compliance. The company was founded by John R. Garboe in 1863 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Algemeen Adviseur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Orrick, Herrington & Sutcliffe LLP
![]() Orrick, Herrington & Sutcliffe LLP Miscellaneous Commercial ServicesCommercial Services Orrick, Herrington & Sutcliffe LLP engages in the provision of legal services. Its practices include: antitrust and competition; banking and finance; capital markets; copyright, trademark and false advertising; cyber, privacy and data innovation; employment law and litigation; energy; financial services litigation; global compliance and regulatory, infrastructure; intellectual property; patents; public finance; real estate; securities litigation; supreme court and appellate; tax advocacy; technology transactions; trials; and white collar, investigations, securities litigation and compliance. The company was founded by John R. Garboe in 1863 and is headquartered in San Francisco, CA. | Commercial Services |